Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

U0126

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Promega

Drug class:

MEK1 inhibitor, MEK2 inhibitor

Related drugs:

ESRP1-RAF1 fusion	Prostate Cancer	ESRP1-RAF1 fusion	Prostate Cancer	U0126 Sensitive: D – Preclinical U0126 Sensitive : D	U0126 Sensitive: D – Preclinical U0126 Sensitive : D
SLC45A3-BRAF fusion	Prostate Cancer	SLC45A3-BRAF fusion	Prostate Cancer	U0126 Sensitive: D – Preclinical U0126 Sensitive : D	U0126 Sensitive: D – Preclinical U0126 Sensitive : D
EML4-ALK fusion	Non Small Cell Lung Cancer	EML4-ALK fusion	Non Small Cell Lung Cancer	ceritinib + U0126 Sensitive: D – Preclinical ceritinib + U0126 Sensitive : D	ceritinib + U0126 Sensitive: D – Preclinical ceritinib + U0126 Sensitive : D
TERT overexpression	Renal Cell Carcinoma	TERT overexpression	Renal Cell Carcinoma	U0126 Sensitive: D – Preclinical U0126 Sensitive : D	U0126 Sensitive: D – Preclinical U0126 Sensitive : D
NRAS G12D	Acute Lymphocytic Leukemia	NRAS G12D	Acute Lymphocytic Leukemia	U0126 Sensitive: D – Preclinical U0126 Sensitive : D	U0126 Sensitive: D – Preclinical U0126 Sensitive : D
GNAQ Q209L	Uveal Melanoma	GNAQ Q209L	Uveal Melanoma	U0126 Sensitive: D – Preclinical U0126 Sensitive : D	U0126 Sensitive: D – Preclinical U0126 Sensitive : D
BRAF K601E	Melanoma	BRAF K601E	Melanoma	U0126 Sensitive: D – Preclinical U0126 Sensitive : D	U0126 Sensitive: D – Preclinical U0126 Sensitive : D
BRAF V600E	Melanoma	BRAF V600E	Melanoma	U0126 Sensitive: D – Preclinical U0126 Sensitive : D	U0126 Sensitive: D – Preclinical U0126 Sensitive : D
BRAF G469E	Melanoma	BRAF G469E	Melanoma	U0126 Resistant: D – Preclinical U0126 Resistant : D	U0126 Resistant: D – Preclinical U0126 Resistant : D
BRAF D549G	Melanoma	BRAF D549G	Melanoma	U0126 Resistant: D – Preclinical U0126 Resistant : D	U0126 Resistant: D – Preclinical U0126 Resistant : D